Digestive Diseases and Sciences

, Volume 53, Issue 4, pp 1020–1024 | Cite as

Medication Non-adherence is Associated with Increased Medical Health Care Costs

  • Sunanda KaneEmail author
  • Fadia Shaya
Original Paper


Background and Aims Non-adherence to 5-aminosalicylic acid (5-ASA) is associated with adverse outcomes; however, no data exist regarding cost and non-adherence. Our aim was to determine the association between adherence to maintenance therapy and healthcare costs. Methods Patients in the Maryland CareFirst BlueCross BlueShield program with a follow-up of more than 1 month who had been prescribed at least one 5-ASA preparation during the period 1 January 2002 to 31 December 2004 were included. Non-adherence was defined as failure to refill a prescription claim, and a medication possession ratio was calculated. Generalized linear models were built to determine the association between annual average cost per patient. Results A total of 4313 patients were included, although only 57% were adherent with their index medication. The mean medication possession ratio ranged from 72% for Azulfidine to 82% for generic sulfasalazine. A twofold difference in gastroenterology-related inpatient cost in non-adherent versus adherent patients (22.8% vs 11.7%, P < 0.01) was observed. Non-adherence also incurred more costs for outpatient services and office visits. In multivariate analysis, patients who were persistent with their medications incurred 12.5% lower medical costs (P = 0.03). Conclusions Adherence remains low over time. Non-adherence was associated with higher health care costs for both in- and outpatient settings. Patients need educated regarding non-adherence and increased costs.


Ulcerative colitis Mesalamine Health care cost Medication adherence 


  1. 1.
    Cramer JA (2004) A systematic review of adherence with medications for diabetes. Diabetes Care 27:1218–1224PubMedCrossRefGoogle Scholar
  2. 2.
    Murphy DA, Sarr M, Durako SJ, Moscicki A-B, Wilson CM, Muenz LR (2003) Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med 157:249–255PubMedCrossRefGoogle Scholar
  3. 3.
    Loghman-Adham M (2003) Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 9:155–171PubMedGoogle Scholar
  4. 4.
    Peura D (1998) Helicobacter pylori: rational management options. Am J Med 105:424–430PubMedCrossRefGoogle Scholar
  5. 5.
    DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW (2002) Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 40:794–811PubMedCrossRefGoogle Scholar
  6. 6.
    World HO (2003) Adherence to long-term therapies. Evidence for action. Available at conditions/adherencereport/en/ Accessed August 2006
  7. 7.
    Rudd P (1995) Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J 130:572–579PubMedCrossRefGoogle Scholar
  8. 8.
    Morris AD, Brennan GM, MacDonald TM, Donnan PT (2000) Population-based adherence to prescribed medication in type 2 diabetes: a cause for concern. Diabetes 49(Suppl 1):A76Google Scholar
  9. 9.
    Kane S, Huo D, Aikens J, Hanauer S (2003) Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 114:39–43PubMedCrossRefGoogle Scholar
  10. 10.
    Kaiser Family Foundation. Maryland: Distribution of non-elderly 0–64 by insurance status, state data 2001–2002, US 2002. State Health Facts Online, (accessed on March 10, 2006)Google Scholar
  11. 11.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidities in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMedCrossRefGoogle Scholar
  12. 12.
    Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619PubMedCrossRefGoogle Scholar
  13. 13.
    Kane SV, Cohen RD, Aikens JE, Hanauer SB (2001) Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 96:2929–2933PubMedCrossRefGoogle Scholar
  14. 14.
    Bernstein CN, Papineau N, Zajaczkowski J et al (2000) Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol 95:677–683PubMedCrossRefGoogle Scholar
  15. 15.
    Hay JW, Hay AR (1992) Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 14:309–317PubMedCrossRefGoogle Scholar
  16. 16.
    Shaya FT, El Khoury AC, Wong W et al (2006) Persistence with pharmacotherapy for gastrointestinal disease: associated costs of health care. P&T 31(11):657–665Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Mayo ClinicRochesterUSA
  2. 2.Analysis GroupUniversity of MarylandBaltimoreUSA

Personalised recommendations